sellWeak
Astrid Borkowski sold $287k of HLVX
Chief Medical Officer at HilleVax, Inc.. 20,000 shares at an average of $14.35, traded Dec 1, 2023, filed Dec 5, 2023.
Warning score
34Value
$287k
20,000 shares
Holdings after
175,193
-10% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +14Trade size$287k at market
- +5Share of holdings soldSold 10% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-068230, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | SOpen-market sale Common Stock | -10,000 | $14.20 | $142k | 185,193 | Dec 5, 2023 |
| Dec 4, 2023 | SOpen-market sale Common Stock | -10,000 | $14.50 | $145k | 175,193 | Dec 5, 2023 |
Related signals
Other insiders at HilleVax, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | HilleVax, Inc. | Robert Hershberg See Remarks | $49k 26,535 shares | -2% | |
| 30Weak | HilleVax, Inc. | Shane Maltbie Chief Financial Officer | $15k 8,291 shares | -9% | |
| 8Weak | HilleVax, Inc. | Aditya Kohli director | $266k 18,000 shares | -2% | |
| 5Weak | HilleVax, Inc. | Aditya Kohli director | $97k 6,898 shares | -1% | |
| 39Weak | HilleVax, Inc. | Patrick J Heron director, owner | $128k 8,850 shares | +0% | |
| 8Weak | HilleVax, Inc. | Aditya Kohli director | $264k 18,000 shares | -2% | |
| 36Weak | HilleVax, Inc. | Sean McLoughlin Chief Operating Officer | $21k 1,250 shares | - | |
| 20Weak | HilleVax, Inc. | Aditya Kohli director | $986M 18,000 shares | -2% | |
| 10Weak | HilleVax, Inc. | Aditya Kohli director | $336k 18,000 shares | -2% | |
| 23Weak | HilleVax, Inc. | Aditya Kohli director | $269k 18,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.